{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:42:37Z","timestamp":1790772157854,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ejps.2011.04.009","type":"journal-article","created":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T22:03:22Z","timestamp":1303509802000},"page":"141-150","source":"Crossref","is-referenced-by-count":57,"title":["Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers"],"prefix":"10.1016","volume":"43","author":[{"given":"Graham","family":"Lappin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shishikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeline","family":"Jochemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard John","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Gesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brian Houston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berend","family":"Oosterhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole J.","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Grynkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Alder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejps.2011.04.009_b0315","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/clpt.1982.111","article-title":"Obesity, sex, and acetaminophen disposition","volume":"31","author":"Abernethy","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5-6","key":"10.1016\/j.ejps.2011.04.009_b0320","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/j.1552-4604.1974.tb02312.x","article-title":"Bioavailability studies of acetaminophen and nitrofurantoin","volume":"14","author":"Albert","year":"1974","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejps.2011.04.009_b0005","first-page":"435","article-title":"Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia","volume":"7","author":"Arboix","year":"1985","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejps.2011.04.009_b0010","first-page":"61","article-title":"Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?","volume":"12","author":"Beaumont","year":"2009","journal-title":"Curr. Opin. Drug. Discov. Devel."},{"issue":"4","key":"10.1016\/j.ejps.2011.04.009_b0015","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/0091270006299092","article-title":"American college of clinical pharmacology position statement on the use of microdosing in the drug development process","volume":"47","author":"Bertino","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2011.04.009_b0020","series-title":"Goodman and Gilman\u2019s, The Pharmacological Basis of Therapeutics","author":"Brunton","year":"2006"},{"issue":"2","key":"10.1016\/j.ejps.2011.04.009_b0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/j.1552-4604.1989.tb03296.x","article-title":"Propafenone disposition in renal insufficiency and renal failure","volume":"29","author":"Burgess","year":"1989","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2011.04.009_b0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/j.1552-4604.1992.tb03784.x","article-title":"Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial","volume":"32","author":"Chu","year":"1992","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2011.04.009_b0035","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1128\/AAC.36.5.1147","article-title":"Absolute bioavailability of clarithromycin after oral administration in humans","volume":"36","author":"Chu","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejps.2011.04.009_b0040","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1128\/AAC.36.11.2447","article-title":"Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses","volume":"36","author":"Chu","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejps.2011.04.009_b0045","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/j.1552-4604.1992.tb03809.x","article-title":"Clarithromycin pharmacokinetics in healthy young and elderly volunteers","volume":"32","author":"Chu","year":"1992","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2011.04.009_b0325","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cpt1978244420","article-title":"Kinetics of acetaminophen absorption and gastric emptying in man","volume":"24","author":"Clements","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejps.2011.04.009_b0050","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1213\/00000539-199808000-00040","article-title":"A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers","volume":"87","author":"Crighton","year":"1998","journal-title":"Anesth. Analg."},{"issue":"5","key":"10.1016\/j.ejps.2011.04.009_b0055","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/dmd.110.036566","article-title":"Prediction of drug clearance by sulfation \u2013 utility of human hepatic and intestinal cytosolic data","volume":"39","author":"Cubitt","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"Suppl. A","key":"10.1016\/j.ejps.2011.04.009_b0310","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0195-6701(91)90215-T","article-title":"The pharmacokinetics of clarithromycin and its 14-OH metabolite","volume":"19","author":"Davey","year":"1991","journal-title":"J. Hosp. Infect."},{"issue":"5","key":"10.1016\/j.ejps.2011.04.009_b0065","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2165\/00003495-199243050-00010","article-title":"Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache","volume":"43","author":"Dechant","year":"1992","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejps.2011.04.009_b0330","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/clpt.1982.24","article-title":"Acetaminophen kinetics in the elderly","volume":"31","author":"Divoll","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ejps.2011.04.009_b0335","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1532-5415.1982.tb07093.x","article-title":"Age does not alter acetaminophen absorption","volume":"30","author":"Divoll","year":"1982","journal-title":"J. Am. Geriatr. Soc."},{"issue":"7","key":"10.1016\/j.ejps.2011.04.009_b0070","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/0006-2952(94)90397-2","article-title":"Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver","volume":"47","author":"Dixon","year":"1994","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2011.04.009_b0340","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00609984","article-title":"Paracetamol (acetaminophen) kinetics in patients with Gilber\u2019s syndrome","volume":"13","author":"Douglas","year":"1978","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2011.04.009_b0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0928-0987(97)00073-0","article-title":"Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration","volume":"6","author":"Duquesnoy","year":"1998","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2011.04.009_b0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/39.1.5","article-title":"The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection","volume":"39","author":"Erah","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.ejps.2011.04.009_b0085","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00228-007-0443-9","article-title":"Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients","volume":"64","author":"Ferrari","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2011.04.009_b0090","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0090-9556(25)08537-X","article-title":"Metabolism and disposition of clarithromycin in man","volume":"18","author":"Ferrero","year":"1990","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.ejps.2011.04.009_b0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-198207020-00001","article-title":"Clinical pharmacokinetics of paracetamol","volume":"7","author":"Forrest","year":"1982","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.ejps.2011.04.009_b0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000116756","article-title":"The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan","volume":"31","author":"Fowler","year":"1991","journal-title":"Eur. Neurol."},{"issue":"3","key":"10.1016\/j.ejps.2011.04.009_b0105","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00003088-199325030-00003","article-title":"Clarithromycin clinical pharmacokinetics","volume":"25","author":"Fraschini","year":"1993","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejps.2011.04.009_b0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4155\/bio.10.6","article-title":"Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data","volume":"2","author":"Garner","year":"2010","journal-title":"Bioanalysis"},{"issue":"2","key":"10.1016\/j.ejps.2011.04.009_b0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00614557","article-title":"Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration","volume":"34","author":"Giani","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2011.04.009_b0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/clpt.1990.146","article-title":"Comparison of the pharmacodynamic effects of intravenous and oral propafenone","volume":"48","author":"Haefeli","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2011.04.009_b0125","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s11095-010-0218-3","article-title":"Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view","volume":"27","author":"Halifax","year":"2010","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejps.2011.04.009_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199121010-00001","article-title":"Clinical pharmacokinetics of propafenone","volume":"21","author":"Hii","year":"1991","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.ejps.2011.04.009_b0135","first-page":"763","article-title":"Investigations on the pharmacokinetics of propafenone in man","volume":"33","author":"Hollmann","year":"1983","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejps.2011.04.009_b0140","unstructured":"ICH-M3, 2009. ICH Topic M3 Note for Guidance on non-clinical safety pharmacology studies for human pharmaceuticals CPMP\/ICH\/286\/95 (December 2009)."},{"issue":"17","key":"10.1016\/j.ejps.2011.04.009_b0145","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.4155\/bio.09.107","article-title":"Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge","volume":"1","author":"Ings","year":"2009","journal-title":"Bioanalysis"},{"issue":"6","key":"10.1016\/j.ejps.2011.04.009_b0150","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/dmd.104.002550","article-title":"Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity","volume":"33","author":"Komura","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.ejps.2011.04.009_b0155","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF00193709","article-title":"Single dose pharmacokinetics of sumatriptan in healthy volunteers","volume":"47","author":"Lacey","year":"1995","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2011.04.009_b0160","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4155\/bio.09.177","article-title":"Microdosing: current and the future","volume":"2","author":"Lappin","year":"2010","journal-title":"Bioanalysis"},{"issue":"12","key":"10.1016\/j.ejps.2011.04.009_b0165","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1517\/17425250802531767","article-title":"The utility of microdosing over the past 5 years","volume":"4","author":"Lappin","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.ejps.2011.04.009_b0170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clpt.2006.05.008","article-title":"Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs","volume":"80","author":"Lappin","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ejps.2011.04.009_b0175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/17425255.2.3.419","article-title":"The use of isotopes in the determination of absolute bioavailability of drugs in humans","volume":"2","author":"Lappin","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2011.04.009_b0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejps.2010.03.009","article-title":"Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability","volume":"40","author":"Lappin","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2011.04.009_b0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ab.2008.03.026","article-title":"High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization","volume":"378","author":"Lappin","year":"2008","journal-title":"Anal. Biochem."},{"issue":"3","key":"10.1016\/j.ejps.2011.04.009_b0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2125.2009.03397.x","article-title":"Early human studies of investigational agents: dose or microdose","volume":"67","author":"Lewis","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2011.04.009_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2005.12.041","article-title":"Target-mediated drug disposition and dynamics","volume":"72","author":"Mager","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejps.2011.04.009_b0200","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2005.12.019","article-title":"In vitro\u2013in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises","volume":"71","author":"Miners","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2011.04.009_b0205","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0149-2918(02)85134-7","article-title":"The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers","volume":"24","author":"Moore","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2011.04.009_b0210","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/jps.2600730806","article-title":"Renal clearance and serum protein binding of acetaminophen and its major conjugates in humans","volume":"73","author":"Morris","year":"1984","journal-title":"J. Pharm. Sci."},{"issue":"2\u20133","key":"10.1016\/j.ejps.2011.04.009_b0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/j.1552-4604.1982.tb02662.x","article-title":"Phenobarbital pharmacokinetics and bioavailability in adults","volume":"22","author":"Nelson","year":"1982","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2011.04.009_b0220","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2011.04.009_b0225","doi-asserted-by":"crossref","unstructured":"Pang, K.S., Durk, M.R., 2010. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J. Pharmacokinet. Pharmacodyn.","DOI":"10.1007\/s10928-010-9185-x"},{"issue":"14","key":"10.1016\/j.ejps.2011.04.009_b0230","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/0006-2952(81)90206-9","article-title":"Conjugation kinetics of acetaminophen by the perfused rat liver preparation","volume":"30","author":"Pang","year":"1981","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2011.04.009_b0235","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199855060-00020","article-title":"Sumatriptan. An updated review of its use in migraine","volume":"55","author":"Perry","year":"1998","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejps.2011.04.009_b0345","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2125.1979.tb00922.x","article-title":"Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs","volume":"7","author":"Perucca","year":"1979","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.ejps.2011.04.009_b0350","doi-asserted-by":"crossref","first-page":"291S","DOI":"10.1111\/j.1365-2125.1980.tb01812.x","article-title":"Kinetics and metabolism of paracetamol and phenacetin","volume":"10","author":"Prescott","year":"1980","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2011.04.009_b0355","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00607678","article-title":"Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration","volume":"11","author":"Rawlins","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2011.04.009_b0240","doi-asserted-by":"crossref","unstructured":"Rowland, M., 2007. Commentary on ACCP position statement on the use of microdosing in the drug development process. J. Clin. Pharmacol. 47(12), 1595\u20131596 (author reply 1597\u20131598).","DOI":"10.1177\/0091270007310548"},{"issue":"10","key":"10.1016\/j.ejps.2011.04.009_b0245","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/0091270005280051","article-title":"The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers","volume":"45","author":"Sarapa","year":"2005","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2011.04.009_b0250","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00003088-199427050-00002","article-title":"Sumatriptan clinical pharmacokinetics","volume":"27","author":"Scott","year":"1994","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.ejps.2011.04.009_b0255","doi-asserted-by":"crossref","first-page":"9D","DOI":"10.1016\/S0002-9149(84)80278-7","article-title":"Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration\u2013response relations","volume":"54","author":"Siddoway","year":"1984","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ejps.2011.04.009_b0260","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/clpt.2010.206","article-title":"Microdose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects","volume":"88","author":"Tozuka","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.ejps.2011.04.009_b0265","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/jps.20309","article-title":"Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability","volume":"94","author":"Varma","year":"2005","journal-title":"J. Pharm. Sci."},{"issue":"2\u20133","key":"10.1016\/j.ejps.2011.04.009_b0270","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/j.1552-4604.1978.tb02428.x","article-title":"Bioavailability of oral and intramuscular phenobarbital","volume":"18","author":"Viswanathan","year":"1978","journal-title":"J. Clin. Pharmacol."},{"issue":"5\u20136","key":"10.1016\/j.ejps.2011.04.009_b0275","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/j.1552-4604.1979.tb02481.x","article-title":"Pharmacokinetics of phenobarbital following single and repeated doses","volume":"19","author":"Viswanathan","year":"1979","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2011.04.009_b0280","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF02336693","article-title":"Nonlinear kinetics of propafenone metabolites in healthy man","volume":"38","author":"Vozeh","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2011.04.009_b0285","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1023\/A:1016211409315","article-title":"Sumatriptan absorption from different regions of the human gastrointestinal tract","volume":"12","author":"Warner","year":"1995","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejps.2011.04.009_b0290","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF01061382","article-title":"Kinetics of phenobarbital in normal subjects and epileptic patients","volume":"23","author":"Wilensky","year":"1982","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2011.04.009_b0295","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jchromb.2007.08.011","article-title":"Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography\/electrospray ionization tandem mass spectrometry","volume":"858","author":"Yamane","year":"2007","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.ejps.2011.04.009_b0300","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1008770519585","article-title":"Oral bioavailability of phenobarbital: a comparison of a solution in Myvacet 9-08, a suspension, and a tablet","volume":"22","author":"Yska","year":"2000","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.ejps.2011.04.009_b0305","doi-asserted-by":"crossref","unstructured":"Zhou, X.J., Garner, R.C., Nicholson, S., Kissling, C.J., Mayers, D., 2009. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J Clin Pharmacol.","DOI":"10.1177\/0091270009343698"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098711001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098711001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T06:20:00Z","timestamp":1741155600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098711001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0928098711001047"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2011.04.009","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}